Hyperactivity of the dopaminergic system in NTS1 and NTS2 null mice

Neuropharmacology

Volumn 58, Issue 8, 2010, Pages 1199-1205

  Liang, Yanqi ^a   Boules, Mona ^a   Li, Zhimin ^a   Williams, Katrina ^a   Miura, Tomofumi ^a   Oliveros, Alfredo ^a   Richelson, Elliott ^a  

^a MAYO CLINIC   (United States)

Author keywords

Amphetamine; Dopamine receptors; Dopamine transporters; Knockout mice; Neurotensin receptors; Schizophrenia

Indexed keywords

AMPHETAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE TRANSPORTER; MESSENGER RNA; NEUROTENSIN; NEUROTENSIN 1; NEUROTENSIN 2; NEUROTENSIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SYNAPTOSOME; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; LOCOMOTION; MALE; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

ANIMALS; CORPUS STRIATUM; DEXTROAMPHETAMINE; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, NEUROTENSIN; RNA, MESSENGER;

EID: 77952887117     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.02.015     Document Type: Article

References (65)

1. Abi-Dargham A., Gil R., Krystal J., Baldwin R.M., Seibyl J.P., Bowers M., van Dyck C.H., Charney D.S., Innis R.B., Laruelle M. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am. J. Psychiatry 1998, 155:761-767.
2. 2 receptors. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:11521-11526.
3. Beauregard M., Ferron A., Descarries L. Opposite effects of neurotensin on dopamine inhibition in different regions of the rat brain: an iontophoretic study. Neuroscience 1992, 47:613-619.
4. Betancur C., Cabrera R., de Kloet E.R., Pelaprat D., Rostene W. Role of endogenous neurotensin in the behavioral and neuroendocrine effects of cocaine. Neuropsychopharmacology 1998, 19:322-332.
5. Binder E.B., Kinkead B., Owens M.J., Nemeroff C.B. Neurotensin and dopamine interactions. Pharmacol. Rev. 2001, 53:453-486.
6. Bolden-Watson C., Watson M.A., Murray K.D., Isackson P.J., Richelson E. Haloperidol but not clozapine increases neurotensin receptor mRNA levels in rat substantia nigra. J. Neurochem. 1993, 61:1141-1143.
7. Boules M., Warrington L., Fauq A., McCormick D., Richelson E. A novel neurotensin analog blocks cocaine- and d-amphetamine-induced hyperactivity. Eur. J. Pharmacol. 2001, 426:73-76.
8. Burgevin M.C., Castel M.N., Quarteronet D., Chevet T., Laduron P.M. Neurotensin increases tyrosine hydroxylase messenger RNA-positive neurons in substantia nigra after retrograde axonal transport. Neuroscience 1992, 49:627-633.
9. Burgevin M.C., Laduron P.M., Quarteronnet D., Chevet T., Castel M.N. Striatal injection of neurotensin increases tyrosine hydroxylase mRNA in substantia nigra. Ann. N. Y. Acad. Sci. 1992, 668:311-313.
10. Carlier P.R., Lo M.M., Lo P.C., Richelson E., Tatsumi M., Reynolds I.J., Sharma T.A. Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group. Bioorg. Med. Chem. Lett. 1998, 8:487-492.
11. Carlsson A., Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol. (Copenh.) 1963, 20:140-144.
12. Carlsson A., Waters N., Carlsson M.L. Neurotransmitter interactions in schizophrenia - therapeutic implications. Biol. Psychiatry 1999, 46:1388-1395.
13. Chalon P., Vita N., Kaghad M., Guillemot M., Bonnin J., Delpech B., Le Fur G., Ferrara P., Caput D. Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Lett. 1996, 386:91-94.
14. Chartoff E.H., Szczypka M.S., Palmiter R.D., Dorsa D.M. Endogenous neurotensin attenuates dopamine-dependent locomotion and stereotypy. Brain Res. 2004, 1022:71-80.
15. Cusack B., Boules M., Tyler B.M., Fauq A., McCormick D.J., Richelson E. Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol. Brain Res. 2000, 856:48-54.
16. De Lean A., Hancock A.A., Lefkowitz R.J. Validation and statistical analysis of a computer modeling method for quantitative analysis of radioligand binding data for mixtures of pharmacological receptor subtypes. Mol. Pharmacol. 1982, 21:5-16.
17. 2 receptors in the rat nucleus accumbens shell. Synapse 2004, 52:176-187.
18. Dobner P.R., Fadel J., Deitemeyer N., Carraway R.E., Deutch A.Y. Neurotensin-deficient mice show altered responses to antipsychotic drugs. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:8048-8053.
19. Ervin G.N., Birkemo L.S., Nemeroff C.B., Prange A.J. Neurotensin blocks certain amphetamine-induced behaviours. Nature 1981, 291:73-76.
20. Feifel D., Pang Z., Shilling P.D., Melendez G., Schreiber R., Button D. Sensorimotor gating in neurotensin-1 receptor null mice. Neuropharmacology 2010, 58:173-178.
21. Feifel D., Reza T.L., Wustrow D.J., Davis M.D. Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist. J. Pharmacol. Exp. Ther. 1999, 288:710-713.
22. Ford A.P., Marsden C.A. In vivo neurochemical and behavioural effects of intracerebrally administered neurotensin and D-Trp11-neurotensin on mesolimbic and nigrostriatal dopaminergic function in the rat. Brain Res. 1990, 534:243-250.
23. 2 receptors via intramembrane receptor-receptor interactions. Relevance for Parkinson's disease and schizophrenia. Neurochem. Int. 1992, 20(Suppl.):215S-224S.
24. 2 receptors as a major mechanism for the neuroleptic-like action of neurotensin. Ann. N. Y. Acad. Sci. 1992, 668:186-204.
25. Gainetdinov R.R., Mohn A.R., Caron M.G. Genetic animal models: focus on schizophrenia. Trends Neurosci. 2001, 24:527-533.
26. Gully D., Canton M., Boigegrain R., Jeanjean F., Molimard J.C., Poncelet M., Gueudet C., Heaulme M., Leyris R., Brouard A., et al. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:65-69.
27. Jennes L., Stumpf W.E., Kalivas P.W. Neurotensin: topographical distribution in rat brain by immunohistochemistry. J. Comp. Neurol. 1982, 210:211-224.
28. Jolicoeur F.B., De Michele G., Barbeau A., St-Pierre S. Neurotensin affects hyperactivity but not stereotypy induced by pre and post synaptic dopaminergic stimulation. Neurosci. Biobehav. Rev. 1983, 7:385-390.
29. Jolicoeur F.B., Gagne M.A., Rivest R., Drumheller A., St-Pierre S. Atypical neuroleptic-like behavioral effects of neurotensin. Brain Res. Bull. 1993, 32:487-491.
30. Kalivas P.W., Burgess S.K., Nemeroff C.B., Prange A.J. Behavioral and neurochemical effects of neurotensin microinjection into the ventral tegmental area of the rat. Neuroscience 1983, 8:495-505.
31. Kalivas P.W., Nemeroff C.B., Prange A.J. Neurotensin microinjection into the nucleus accumbens antagonizes dopamine-induced increase in locomotion and rearing. Neuroscience 1984, 11:919-930.
32. Kinkead B., Dobner P.R., Egnatashvili V., Murray T., Deitemeyer N., Nemeroff C.B. Neurotensin-deficient mice have deficits in prepulse inhibition: restoration by clozapine but not haloperidol, olanzapine, or quetiapine. J. Pharmacol. Exp. Ther. 2005, 315:256-264.
33. Kinkead B., Nemeroff C.B. Neurotensin, schizophrenia, and antipsychotic drug action. Int. Rev. Neurobiol. 2004, 59:327-349.
34. Kitabgi P., Herve D., Studler J.M., Tramu G., Rostene W., Tassin J.P. Encephale 1989, 91-94. 15 Spec No.
35. Lambert P.D., Gross R., Nemeroff C.B., Kilts C.D. Anatomy and mechanisms of neurotensin-dopamine interactions in the central nervous system. Ann. N. Y. Acad. Sci. 1995, 757:377-389.
36. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., Innis R.B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:9235-9240.
37. Laruelle M., Frankle W.G., Narendran R., Kegeles L.S., Abi-Dargham A. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation. Clin. Ther. 2005, 27(Suppl. A):S16-S24.
38. Leeman S.E., Carraway R.E. Neurotensin: discovery, isolation, characterization, synthesis and possible physiological roles. Ann. N. Y. Acad. Sci. 1982, 400:1-16.
39. Leonetti M., Brun P., Clerget M., Steinberg R., Soubrie P., Renaud B., Suaud-Chagny M.F. Specific involvement of neurotensin type 1 receptor in the neurotensin-mediated in vivo dopamine efflux using knock-out mice. J. Neurochem. 2004, 89:1-6.
40. 2 receptors in rat nucleus accumbens: a receptor binding and microdialysis study. J. Neural. Transm. Gen. Sect. 1995, 102:125-137.
41. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
42. Mazella J., Botto J.M., Guillemare E., Coppola T., Sarret P., Vincent J.P. Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain. J. Neurosci. 1996, 16:5613-5620.
43. Mechanic J.A., Sutton J.E., Berson A.E., Wu X., Kwan J., Schreiber R., Pang Z., Button D.C. Involvement of the neurotensin receptor 1 in the behavioral effects of two neurotensin agonists, NT-2 and NT69L: lack of hypothermic, antinociceptive and antipsychotic actions in receptor knockout mice. Eur. Neuropsychopharmacol. 2009, 19:466-475.
44. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: from structure to function. Physiol. Rev. 1998, 78:189-225.
45. Munson P.J., Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 1980, 107:220-239.
46. Nemeroff C.B. Neurotensin: perchance an endogenous neuroleptic?. Biol. Psychiatry 1980, 15:283-302.
47. Nemeroff C.B., Luttinger D., Hernandez D.E., Mailman R.B., Mason G.A., Davis S.D., Widerlov E., Frye G.D., Kilts C.A., Beaumont K., Breese G.R., Prange A.J. Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies. J. Pharmacol. Exp. Ther. 1983, 225:337-345.
48. Nemeroff C.B., Youngblood W.W., Manberg P.J., Prange A.J., Kizer J.S. Regional brain concentrations of neuropeptides in Huntington's chorea and schizophrenia. Science 1983, 221:972-975.
49. Paxinos G., Franklin K. The Mouse Brain in Stereotaxic Coordinates 2001, Academic Press, NY.
50. Remaury A., Vita N., Gendreau S., Jung M., Arnone M., Poncelet M., Culouscou J.M., Le Fur G., Soubrie P., Caput D., Shire D., Kopf M., Ferrara P. Targeted inactivation of the neurotensin type 1 receptor reveals its role in body temperature control and feeding behavior but not in analgesia. Brain Res. 2002, 953:63-72.
51. Richelson E., Pfenning M. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur. J. Pharmacol. 1984, 104:277-286.
52. 2 receptors. Neuroreport 1999, 10:2051-2054.
53. Sarhan S., Hitchcock J.M., Grauffel C.A., Wettstein J.G. Comparative antipsychotic profiles of neurotensin and a related systemically active peptide agonist. Peptides 1997, 18:1223-1227.
54. Sarret P., Esdaile M.J., Perron A., Martinez J., Stroh T., Beaudet A. Potent spinal analgesia elicited through stimulation of NTS2 neurotensin receptors. J. Neurosci. 2005, 25:8188-8196.
55. Sarret P., Perron A., Stroh T., Beaudet A. Immunohistochemical distribution of NTS2 neurotensin receptors in the rat central nervous system. J. Comp. Neurol. 2003, 461:520-538.
56. Seamans J.K., Gorelova N., Durstewitz D., Yang C.R. Bidirectional dopamine modulation of GABAergic inhibition in prefrontal cortical pyramidal neurons. J. Neurosci. 2001, 21:3628-3638.
57. Seamans J.K., Yang C.R. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog. Neurobiol. 2004, 74:1-58.
58. Shi W.X., Bunney B.S. Roles of intracellular cAMP and protein kinase A in the actions of dopamine and neurotensin on midbrain dopamine neurons. J. Neurosci. 1992, 12:2433-2438.
59. Shilling P.D., Richelson E., Feifel D. The effects of systemic NT69L, a neurotensin agonist, on baseline and drug-disrupted prepulse inhibition. Behav. Brain Res. 2003, 143:7-14.
60. Tanaka K., Masu M., Nakanishi S. Structure and functional expression of the cloned rat neurotensin receptor. Neuron 1990, 4:847-854.
61. Tatsumi M., Groshan K., Blakely R.D., Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol. 1997, 340:249-258.
62. Taylor S.F., Koeppe R.A., Tandon R., Zubieta J.K., Frey K.A. In vivo measurement of the vesicular monoamine transporter in schizophrenia. Neuropsychopharmacology 2000, 23:667-675.
63. van Berckel B.N., Kegeles L.S., Waterhouse R., Guo N., Hwang D.R., Huang Y., Narendran R., Van Heertum R., Laruelle M. Modulation of amphetamine-induced dopamine release by group II metabotropic glutamate receptor agonist LY354740 in non-human primates studied with positron emission tomography. Neuropsychopharmacology 2006, 31:967-977.
64. Vita N., Laurent P., Lefort S., Chalon P., Dumont X., Kaghad M., Gully D., Le Fur G., Ferrara P., Caput D. Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor. FEBS Lett. 1993, 317:139-142.
65. Wagstaff J.D., Bush L.G., Gibb J.W., Hanson G.R. Endogenous neurotensin antagonizes methamphetamine-enhanced dopaminergic activity. Brain Res. 1994, 665:237-244.